LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 166

Search options

  1. Book: Rosacea update

    Leyden, James J.

    advances from basic and clinical research

    (Journal of the American Academy of Dermatology ; 69,6, Suppl.)

    2013  

    Author's details guest ed.: James J. Leyden
    Series title Journal of the American Academy of Dermatology ; 69,6, Suppl.
    Collection
    Language English
    Size A4, S65 S. : Ill.
    Publisher Elsevier
    Publishing place S.l.
    Publishing country United States
    Document type Book
    HBZ-ID HT018155329
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: Effects of topical tretinoin on non-sun-exposed protected skin of the elderly: Over 26 years later.

    Leyden, James J

    Journal of the American Academy of Dermatology

    2020  Volume 82, Issue 3, Page(s) 776–777

    MeSH term(s) Skin ; Tretinoin
    Chemical Substances Tretinoin (5688UTC01R)
    Language English
    Publishing date 2020-02-14
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2018.08.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book: Improving acne outcomes with combination therapy

    Leyden, James J.

    (Journal of the American Academy of Dermatology ; 49,3, Suppl.)

    2003  

    Author's details guest ed.: James J. Leyden
    Series title Journal of the American Academy of Dermatology ; 49,3, Suppl.
    Collection
    Language English
    Size 3A S., S. S199 - S232 S. : Ill.
    Publisher Mosby
    Publishing place St. Louis, Mo
    Publishing country United States
    Document type Book
    HBZ-ID HT013782162
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  4. Article: Update: Mechanisms of Topical Retinoids in Acne.

    Dreno, Brigitte / Kang, Sewon / Leyden, James / York, Jean

    Journal of drugs in dermatology : JDD

    2022  Volume 21, Issue 7, Page(s) 734–740

    Abstract: ... clues to the molecular and genetic response to trifarotene in resolving acne. J Drugs Dermatol. 2022;21 ...

    Abstract Topical retinoids are the cornerstone of current acne management due to their actions on multiple facets of acne pathophysiology. Retinoids are a family of compounds that structurally and functionally resemble vitamin A, an essential nutrient with a key role in cellular growth and differentiation. In the skin, retinoids exert their effects by binding retinoic acid receptors (RARs) in the cell nucleus with subsequent regulation of gene transcription. There are three subtypes of RARs, and the topical retinoids currently approved for acne have differing receptor binding profiles which may translate to clinical differences, since the specific RAR subtypes activated dictate the biological response of target cells. The activity of a retinoid depends on cellular transport, receptor-binding pattern and affinity, and the genes activated. This review discusses physiologic pathways in skin that are affected by topical retinoids during acne therapy, with a focus on new data from trifarotene, a retinoid which is highly selective for the RAR-γ receptor. Recently, bioinformatic data comparing gene expression in acne lesions treated with trifarotene versus spontaneously resolving acne lesions showed that trifarotene significantly modulates 67 genes that do not appear in the spontaneously resolving lesion. These genes are involved in cellular migration, activation of adaptive immunity, inflammation, and matrix reorganization. Expression of these trifarotene-regulated genes after treatment and in an active lesion occurred in opposite directions, providing clues to the molecular and genetic response to trifarotene in resolving acne. J Drugs Dermatol. 2022;21(7):734-740. doi:10.36849/JDD.6890.
    MeSH term(s) Acne Vulgaris/drug therapy ; Acne Vulgaris/pathology ; Cell Differentiation ; Humans ; Retinoids/therapeutic use ; Skin/pathology
    Chemical Substances Retinoids
    Language English
    Publishing date 2022-06-21
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2145090-0
    ISSN 1545-9616
    ISSN 1545-9616
    DOI 10.36849/JDD.6890
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Book: Emerging topical retinoid therapies

    Leyden, James J.

    (Journal of the American Academy of Dermatology ; 38,4, Suppl.)

    1998  

    Author's details guest ed.: James J. Leyden
    Series title Journal of the American Academy of Dermatology ; 38,4, Suppl.
    Collection
    Keywords Retinoids / therapeutic use
    Language English
    Size S30 S. : graph. Darst.
    Publisher Mosby
    Publishing place St. Louis, Mo
    Publishing country United States
    Document type Book
    HBZ-ID HT008407587
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  6. Article ; Online: Recent advances in the use of adapalene 0.1%/benzoyl peroxide 2.5% to treat patients with moderate to severe acne.

    Leyden, James

    The Journal of dermatological treatment

    2016  Volume 27 Suppl 1, Page(s) S4–13

    Abstract: The central role of inflammation in acne is now more clearly understood. Adapalene, a third-generation topical retinoid, down-regulates toll-like receptor 2 expression and inhibits activator protein-1 activity. In a fixed-dose combination, adapalene and ... ...

    Abstract The central role of inflammation in acne is now more clearly understood. Adapalene, a third-generation topical retinoid, down-regulates toll-like receptor 2 expression and inhibits activator protein-1 activity. In a fixed-dose combination, adapalene and benzoyl peroxide (BPO) act synergistically on inflammatory patterns through regulation of innate immunity. In addition to reducing inflammatory and non-inflammatory lesions, adapalene/BPO helps prevent lesion and microcomedone formation. The combination of a topical retinoid and antimicrobial agent remains the preferred approach for almost all patients with acne. In cases of more severe disease, there is a clinical benefit in combining adapalene/BPO with an oral antibiotic for 12 weeks. Most recently, adapalene/BPO plus doxycycline 200 mg was found to be highly effective when compared with isotretinoin in the treatment of patients with severe acne with nodules. Long-term maintenance therapy is needed for most patients. Retinoids are the preferred agents, with BPO added in patients with more severe disease if needed. Adapalene is anticomedogenic, reduces comedones and has anti-inflammatory properties, while BPO is a unique antimicrobial agent not shown to induce microbial resistance after more than 50 years of use. Maintenance therapy for 6 months with adapalene/BPO prevents relapse among patients with severe acne and continues to reduce disease symptoms.
    MeSH term(s) Acne Vulgaris/drug therapy ; Adapalene/administration & dosage ; Anti-Bacterial Agents/administration & dosage ; Benzoyl Peroxide/administration & dosage ; Dermatologic Agents/administration & dosage ; Doxycycline/administration & dosage ; Doxycycline/therapeutic use ; Drug Combinations ; Gels ; Humans ; Inflammation/drug therapy ; Isotretinoin/therapeutic use
    Chemical Substances Anti-Bacterial Agents ; Dermatologic Agents ; Drug Combinations ; Gels ; Adapalene (1L4806J2QF) ; Isotretinoin (EH28UP18IF) ; Doxycycline (N12000U13O) ; Benzoyl Peroxide (W9WZN9A0GM)
    Language English
    Publishing date 2016
    Publishing country England
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 1036299-x
    ISSN 1471-1753 ; 0954-6634
    ISSN (online) 1471-1753
    ISSN 0954-6634
    DOI 10.3109/09546634.2016.1145338
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: How does our increased understanding of the role of inflammation and innate immunity in acne impact treatment approaches?

    Leyden, James

    The Journal of dermatological treatment

    2016  Volume 27 Suppl 1, Page(s) S1–3

    Abstract: A supplement article recently published in the Journal of the European Academy of Dermatology and Venereology by Dréno et al., members of the Global Alliance to Improve Outcomes in Acne group, summarized the data for the emerging concept that ... ...

    Abstract A supplement article recently published in the Journal of the European Academy of Dermatology and Venereology by Dréno et al., members of the Global Alliance to Improve Outcomes in Acne group, summarized the data for the emerging concept that inflammation in general and the innate immune system specifically play a central role in the pathogenesis of acne. This review, entitled "Understanding innate immunity and inflammation in acne: implications for management", also discusses the impact of different treatment options on the innate immune response and inflammation. The aim of the present summary is to provide a synopsis of the key points made in the paper, from the members of the Global Alliance, as relevant to the main article within this supplement: "Recent advances in the use of adapalene 0.1%/benzoyl peroxide 2.5% to treat acne patients with moderate to severe acne".
    MeSH term(s) Acne Vulgaris/drug therapy ; Adapalene/administration & dosage ; Benzoyl Peroxide/administration & dosage ; Benzoyl Peroxide/therapeutic use ; Drug Combinations ; Humans ; Immunity, Innate ; Inflammation/drug therapy ; Inflammation/pathology
    Chemical Substances Drug Combinations ; Adapalene (1L4806J2QF) ; Benzoyl Peroxide (W9WZN9A0GM)
    Language English
    Publishing date 2016
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1036299-x
    ISSN 1471-1753 ; 0954-6634
    ISSN (online) 1471-1753
    ISSN 0954-6634
    DOI 10.3109/09546634.2016.1145337
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Understanding and Reducing the Risk for Acne Scarring.

    Leyden, James J

    Seminars in cutaneous medicine and surgery

    2015  Volume 34, Issue 5 Suppl, Page(s) S89–91

    Abstract: Scarring is a lifelong, physically disfiguring and often emotionally debilitating sequela resulting from acne vulgaris. Nearly 80% of patients have some scarring and 50% have clinically relevant scarring. Although the extent, duration, and intensity of ... ...

    Abstract Scarring is a lifelong, physically disfiguring and often emotionally debilitating sequela resulting from acne vulgaris. Nearly 80% of patients have some scarring and 50% have clinically relevant scarring. Although the extent, duration, and intensity of inflammation are important risk factors, scarring also can develop in patients with relatively mild inflammation. Assessment of scarring should be part of the evaluation in all patients with acne and should be a consideration in determining treatment. Semin Cutan Med Surg 34(supp5):S89-S91 © 2015 published by Frontline Medical Communications.
    Language English
    Publishing date 2015-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1355511-x
    ISSN 1558-0768 ; 1085-5629
    ISSN (online) 1558-0768
    ISSN 1085-5629
    DOI 10.12788/j.sder.2015.0164
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The evolving view of rosacea.

    Leyden, James J

    Journal of the American Academy of Dermatology

    2013  Volume 69, Issue 6 Suppl 1, Page(s) S1

    MeSH term(s) Humans ; Rosacea
    Language English
    Publishing date 2013-12
    Publishing country United States
    Document type Introductory Journal Article
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2013.07.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel.

    Leyden, James J

    Journal of drugs in dermatology : JDD

    2014  Volume 13, Issue 6, Page(s) 685–688

    Abstract: Objective: Compare the safety and efficacy of 1% and 5% silica encapsulated benzoyl peroxide (E-BPO) in patients with papulopustular rosacea.: Design: Multi-centered randomized, double blind, vehicle controlled parallel group, 12 week treatment in 92 ...

    Abstract Objective: Compare the safety and efficacy of 1% and 5% silica encapsulated benzoyl peroxide (E-BPO) in patients with papulopustular rosacea.
    Design: Multi-centered randomized, double blind, vehicle controlled parallel group, 12 week treatment in 92 patients with papulopustular rosacea. Primary endpoints were dichotomized IGA with success defined as clear/near clear and reduction in inflammatory lesions.
    Patients: 92 patients: 74% graded as moderate IGA, 14% severe and 12% mild. The mean inflammatory lesion count was 24.
    Intervention: Once daily treatment for 12 weeks with vehicle, 1% or 5% E-BPO.
    Results: 1% and 5% E-BPO were superior to vehicle in reducing papulopustular lesions P =0.01 and P =0.02. 5% E-BPO was superior to vehicle for IGA P =0.0013.
    MeSH term(s) Administration, Cutaneous ; Adult ; Aged ; Aged, 80 and over ; Benzoyl Peroxide/administration & dosage ; Benzoyl Peroxide/adverse effects ; Benzoyl Peroxide/therapeutic use ; Dermatologic Agents/administration & dosage ; Dermatologic Agents/adverse effects ; Dermatologic Agents/therapeutic use ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Gels ; Humans ; Male ; Middle Aged ; Rosacea/drug therapy ; Rosacea/pathology ; Severity of Illness Index ; Silicon Dioxide/chemistry ; Treatment Outcome
    Chemical Substances Dermatologic Agents ; Gels ; Silicon Dioxide (7631-86-9) ; Benzoyl Peroxide (W9WZN9A0GM)
    Language English
    Publishing date 2014-06
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 2145090-0
    ISSN 1545-9616
    ISSN 1545-9616
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top